Significance of the catechol-O-methyltransferase gene polymorphism in migraine

被引:0
作者
Erdal, ME
Herken, H
Yilmaz, M
Bayazit, YA [1 ]
机构
[1] Gaziantep Univ, Fac Med, Dept Otolaryngol, Kolejtepe, Gaziantep, Turkey
[2] Gaziantep Univ, Fac Med, Dept Neurol, Kolejtepe, Gaziantep, Turkey
[3] Gaziantep Univ, Fac Med, Dept Psychiat, Kolejtepe, Gaziantep, Turkey
[4] Mersin Univ, Fac Med, Dept Med Biol & Genet, Mersin, Turkey
来源
MOLECULAR BRAIN RESEARCH | 2001年 / 94卷 / 1-2期
关键词
catechol-O-methyltransferase; migraine; polymorphism;
D O I
暂无
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
The objective was to assess the significance of the catechol-o-methyltransferase (COMT) enzyme polymorphism in migraine. For this reason, 62 migraineurs and 64 healthy volunteers were included in the study. The analysis of COMT polymorphism was performed using PCR. The H/H genotype was more frequent in the control group than in the patients group (P = 0.032). The homozygous or heterozygous L allele was over represented in the migraineurs compared with the controls (P = 0.013). The L/L genotype was over represented in the migraineurs who also had a family history of migraine (P = 0.003). There was no relationship between aura and COMT genotypes. In conclusion, the COMT polymorphism may be of potential pharmacological importance regarding the individual differences in the metabolism of catechol drugs in migraineurs. Although altered catechoamine activity due to polymorphism of COMT gene may be one of the mechanisms involved in the pathogenesis of migraine, these mechanisms are not related to presence or absence of aura. (C) 2001 Elsevier Science BY All rights reserved.
引用
收藏
页码:193 / 196
页数:4
相关论文
共 14 条
[1]   Migraine patients show an increased density of dopamine D3 and D4 receptors on lymphocytes [J].
Barbanti, P ;
Fabbrini, G ;
Ricci, A ;
Pascali, MP ;
Bronzetti, E ;
Amenta, F ;
Lenzi, GL ;
Cerbo, R .
CEPHALALGIA, 2000, 20 (01) :15-19
[2]  
Daniels JK, 1996, AM J PSYCHIAT, V153, P268
[3]   Genotype determining low catechol-O-methyltransferase activity as a risk factor for obsessive-compulsive disorder [J].
Karayiorgou, M ;
Altemus, M ;
Galke, BL ;
Goldman, D ;
Murphy, DL ;
Ott, J ;
Gogos, JA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (09) :4572-4575
[4]   Human catechol-O-methyltransferase pharmacogenetics: Description of a functional polymorphism and its potential application to neuropsychiatric disorders [J].
Lachman, HM ;
Papolos, DF ;
Saito, T ;
Yu, YM ;
Szumlanski, CL ;
Weinshilboum, RM .
PHARMACOGENETICS, 1996, 6 (03) :243-250
[5]  
Lachman HM, 1996, AM J MED GENET, V67, P468, DOI 10.1002/(SICI)1096-8628(19960920)67:5<468::AID-AJMG5>3.0.CO
[6]  
2-G
[7]  
Lai M, 1997, INT J CLIN PHARM RES, V17, P101
[8]   Dopamine and migraine: a review of pharmacological, biochemical, neurophysiological, and therapeutic data [J].
Mascia, A ;
Afra, J ;
Schoenen, J .
CEPHALALGIA, 1998, 18 (04) :174-182
[9]   Molecular genetics of migraine headaches: a review [J].
Montagna, P .
CEPHALALGIA, 2000, 20 (01) :3-14
[10]  
Nappi G, 2000, FUNCT NEUROL, V15, P87